Hydrofera Blue READY-Transfer Antibacterial Foam Wound Care Dressing Approved for Sale in Canada

MANCHESTER, Conn. – September 12, 2019 – (Newswire.com)

Hydrofera, LLC, announced today that its Hydrofera Blue READY-Transfer antibacterial foam dressing has been approved by Health Canada for sale in Canada.

The Hydrofera Blue READY-Transfer antibacterial foam dressing provides broad-spectrum, antibacterial protection to help manage bioburden, is noncytotoxic and requires no hydration. The dressing features no film backing, which increases exudate management options.

Exudate is transferred at a high rate into secondary absorbent dressings. They are suitable for use on partial and full-thickness wounds and have up to a seven-day wear time. 

Hydrofera Blue READY-Transfer antibacterial foam dressings are available in three sizes: 2.5″ x 2.5″ (6.4 cm x 6.4 cm), 4″ x 5″ (10.2 cm x 12.7 cm) and 8″ x 8″ (20.3 cm x 20.3 cm).

Hydrofera Blue READY-Transfer antibacterial foam dressings join Hydrofera Blue CLASSIC antibacterial foam dressings, Hydrofera Blue READY antibacterial foam dressings and Hydrofera Blue READY-Border antibacterial foam dressings, which are also approved for sale in Canada.

The dressings will be available for sale beginning Oct. 1, 2019 and can be ordered through Appulse Medical at https://appulsemed.com ; 1(860)337-7466;

customerservice@appulsemed.com

About Hydrofera, LLC

Hydrofera, LLC, is the developer of Hydrofera Blue antibacterial wound dressings, an advanced line of wound care products designed to shorten healing times, lower treatment costs and deliver better patient outcomes. The company maintains agreements with every large national medical/surgical distributor and buying group within the U.S. and Canadian healthcare markets. The company’s website is located at: http://hydrofera.test

Read more: http://www.digitaljournal.com/pr/4442724#ixzz5zLE9I9XI

Leave a Reply

Your email address will not be published. Required fields are marked *

Privacy & Terms © Hydrofera | All rights reserved 2024